A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.

A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.

Publication date: Aug 20, 2026

Post-exertional malaise (PEM), the defining feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is increasingly recognized in individuals with Long COVID. Although traditionally viewed as symptom exacerbation and/or emergence of new symptoms following exertion, PEM may reflect disrupted coordination across interconnected physiological systems operating over distinct post-exertional timescales. Such disruption may result in altered post-exertional physiological trajectories that contribute to multisystem manifestations and potential cardiometabolic consequences. This perspective outlines a conceptual approach for investigating PEM through longitudinal assessment of post-exertional physiological trajectories while considering disease severity and underlying cardiometabolic health, including obesity and type 2 diabetes. Integrating these dimensions may help contextualize post-exertional responses, inform future longitudinal cardiometabolic profiling, facilitate patient stratification, and provide a framework for future mechanistic and interventional studies in ME/CFS and Long COVID.

Open Access PDF

Concepts Keywords
Contextualize Cardiometabolic health
Diabetes Coronavirus Infections
Encephalomyelitis COVID-19
Fatigue Diabetes Mellitus, Type 2
Future Fatigue Syndrome, Chronic
Humans
Long COVID
Obesity
Obesity
Pandemics
Pneumonia, Viral
Post-Acute COVID-19 Syndrome
Post-exertional malaise
SARS-CoV-2
Type 2 diabetes

Semantics

Type Source Name
disease MESH myalgic encephalomyelitis
disease MESH Long COVID
disease MESH symptom exacerbation
disease MESH obesity
disease MESH type 2 diabetes
disease MESH Allergy
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK Dimercaprol
disease MESH infection
disease MESH PAIS
disease MESH metabolic syndrome
disease MESH dis
disease MESH bed
drug DRUGBANK Tretamine
disease MESH car
drug DRUGBANK Metformin
drug DRUGBANK Glucagon
disease MESH chronic conditions
drug DRUGBANK Oxygen
disease MESH stroke
disease MESH dys
disease MESH tic
disease MESH syndromes
disease MESH neglected disease
disease MESH Orthostatic Intolerance
disease MESH myelitis
disease MESH COVID 19
disease MESH fac
drug DRUGBANK Tolbutamide
disease MESH Coronavirus Infections
disease MESH Pneumonia Viral

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *